BACKGROUND: Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer (mbc). This study reports clinical benefit and toxicities experienced by women with mbc treated with nab-paclitaxel at the Ottawa Hospital Cancer Centre. METHODS: Women with mbc treated with single-agent nab-paclitaxel between June 2006 and December 2010 were included in this analysis. Retrospective data obtained included demographics, disease characteristics, prior chemotherapy, nab-paclitaxel treatment, toxicity, and survival. Clinical benefit was defined as partial or complete response or stable disease (by clinical or radiologic evaluation, or both) at 6 months or more. RESULTS: Of 43 women (mean age: 57.0 years; range: 34-74 years), most had disease positive for estrogen or progesterone receptor (72.1%, 58.1%), or both. Nab-paclitaxel was administered weekly (qw: 44.2%), every 3 weeks (q3w: 46.5%), q3w switched to qw (7.0%), or qw switched to q3w (2.3%). Median duration of therapy was 5.1 months (qw) and 3.0 months (q3w). Sensory neuropathy was the primary toxicity (45.4% qw, 38.1% q3w; p = 0.62). Clinical benefit was observed in most women (76.2% qw, 57.1% q3w; p = 0.20). Women receiving nab-paclitaxel had a median overall survival of 13.6 months qw (range: 8.1-28.3 months) and 10.8 months q3w (range: 5.9-17.9 months; p = 0.03). Regardless of dosing schedule, women experiencing clinical benefit lived significantly longer than those not experiencing a benefit (17.3 months vs. 7.7 months; hazard ratio: 0.14; 95% confidence interval: 0.06 to 0.33). CONCLUSIONS: Our clinical experience demonstrates that most women treated with nab-paclitaxel experienced some clinical benefit. Patients achieving clinical benefit lived significantly longer than those who did not. Nab-paclitaxel was well tolerated, with the primary toxicity being mild sensory neuropathy. Nab-paclitaxel represents another treatment option, with a favourable toxicity profile, for women with mbc.
BACKGROUND:Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer (mbc). This study reports clinical benefit and toxicities experienced by women with mbc treated with nab-paclitaxel at the Ottawa Hospital Cancer Centre. METHODS:Women with mbc treated with single-agent nab-paclitaxel between June 2006 and December 2010 were included in this analysis. Retrospective data obtained included demographics, disease characteristics, prior chemotherapy, nab-paclitaxel treatment, toxicity, and survival. Clinical benefit was defined as partial or complete response or stable disease (by clinical or radiologic evaluation, or both) at 6 months or more. RESULTS: Of 43 women (mean age: 57.0 years; range: 34-74 years), most had disease positive for estrogen or progesterone receptor (72.1%, 58.1%), or both. Nab-paclitaxel was administered weekly (qw: 44.2%), every 3 weeks (q3w: 46.5%), q3w switched to qw (7.0%), or qw switched to q3w (2.3%). Median duration of therapy was 5.1 months (qw) and 3.0 months (q3w). Sensory neuropathy was the primary toxicity (45.4% qw, 38.1% q3w; p = 0.62). Clinical benefit was observed in most women (76.2% qw, 57.1% q3w; p = 0.20). Women receiving nab-paclitaxel had a median overall survival of 13.6 months qw (range: 8.1-28.3 months) and 10.8 months q3w (range: 5.9-17.9 months; p = 0.03). Regardless of dosing schedule, women experiencing clinical benefit lived significantly longer than those not experiencing a benefit (17.3 months vs. 7.7 months; hazard ratio: 0.14; 95% confidence interval: 0.06 to 0.33). CONCLUSIONS: Our clinical experience demonstrates that most women treated with nab-paclitaxel experienced some clinical benefit. Patients achieving clinical benefit lived significantly longer than those who did not. Nab-paclitaxel was well tolerated, with the primary toxicity being mild sensory neuropathy. Nab-paclitaxel represents another treatment option, with a favourable toxicity profile, for women with mbc.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: William J Gradishar; Dimitry Krasnojon; Sergey Cheporov; Anatoly N Makhson; Georgiy M Manikhas; Alicia Clawson; Paul Bhar; John R McGuire; Jose Iglesias Journal: Clin Breast Cancer Date: 2012-06-23 Impact factor: 3.225
Authors: Dawn L Hershman; Louis H Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; Deborah Fuentes; Danielle Awad; Katherine D Crew Journal: Breast Cancer Res Treat Date: 2010-12-03 Impact factor: 4.872
Authors: Hope S Rugo; William T Barry; Alvaro Moreno-Aspitia; Alan P Lyss; Constance Cirrincione; Eleanor Leung; Erica L Mayer; Michael Naughton; Deborah Toppmeyer; Lisa A Carey; Edith A Perez; Clifford Hudis; Eric P Winer Journal: J Clin Oncol Date: 2015-06-08 Impact factor: 44.544
Authors: Erin R Gardner; William L Dahut; Charity D Scripture; Jacquin Jones; Jeanny B Aragon-Ching; Neil Desai; Michael J Hawkins; Alex Sparreboom; William D Figg Journal: Clin Cancer Res Date: 2008-07-01 Impact factor: 12.531
Authors: Eric P Winer; Donald A Berry; Susan Woolf; David Duggan; Alice Kornblith; Lyndsay N Harris; Richard A Michaelson; Jeffrey A Kirshner; Gini F Fleming; Michael C Perry; Mark L Graham; Stewart A Sharp; Roger Keresztes; I Craig Henderson; Clifford Hudis; Hyman Muss; Larry Norton Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Raffaella Palumbo; Federico Sottotetti; Giuseppe Trifirò; Elena Piazza; Antonella Ferzi; Anna Gambaro; Elena Giulia Spinapolice; Emma Pozzi; Barbara Tagliaferri; Cristina Teragni; Antonio Bernardo Journal: Drug Des Devel Ther Date: 2015-04-15 Impact factor: 4.162